<DOC>
	<DOCNO>NCT00000632</DOCNO>
	<brief_summary>To evaluate safety immune response 100 mcg Env 2-3 antigen administer day 0 , 30 , 180 , 365 . Preliminary immunologic data protocol VEU 005B show evidence development functional antibody form increase peptide bind development neutralize antibody . Evaluation antigen dose potentially great immunogenicity therefore particular interest .</brief_summary>
	<brief_title>A Phase I Clinical Trial Evaluate Safety Immunogenicity 100 mcg Env 2-3 MF59</brief_title>
	<detailed_description>Preliminary immunologic data protocol VEU 005B show evidence development functional antibody form increase peptide bind development neutralize antibody . Evaluation antigen dose potentially great immunogenicity therefore particular interest . Twelve healthy volunteer receive injection 100 mcg Env 2-3 MF59 emulsion two volunteer receive MF59 day 0 , 30 , 180 , 365 . Follow-up continue 6 month last injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Subjects : Normal , healthy adult ( history physical examination ) fully comprehend purpose detail study . Exclusion Criteria Coexisting Condition : Subjects follow condition symptom exclude : Positive syphilis serology ( VDRL ) unless positive test due document clinical event occur treated 5 year prior enrollment . Circulating hepatitis B antigenemia . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease . Evidence depression treatment psychiatric problem past year . Prior Medication : Excluded : Immunosuppressive medication . Prior Treatment : Excluded : Blood transfusion cryoprecipitates within past 6 month . Identifiable highrisk behavior HIV infection , include : history intravenous drug use ; syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) last 6 month ; two sexual partner , sexual contact highrisk partner , precede 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>